Amyloid load in the brain using Pittsburgh compound B ( 11 C-PIB) positron emission tomography (PET) and cerebral glucose metabolism using fluorodeoxyglucose ( 18 F-FDG) PET were evaluated in patients with mild Alzheimer disease (AD, n ¼ 18), mild cognitive impairment (MCI, n ¼ 24), and controls (CTR, n ¼ 18). 11 C-PIB binding potential (BP ND ) was higher in prefrontal cortex, cingulate, parietal cortex, and precuneus in AD compared to CTR or MCI and in prefrontal cortex for MCI compared to CTR. For 18 F-FDG, regional cerebral metabolic rate for glucose (rCMRGlu) was decreased in precuneus and parietal cortex in AD compared to CTR and MCI, with no MCI-CTR differences. For the AD-CTR comparison, precuneus BP ND area under the receiver operating characteristic (ROC) curve (AUC) was 0.938 and parietal cortex rCMRGlu AUC was 0.915; for the combination, AUC was 0.989. 11 C-PIB PET BP ND clearly distinguished diagnostic groups and combined with 18 F-FDG PET rCMRGlu, this effect was stronger. These PET techniques provide complementary information in strongly distinguishing diagnostic groups in crosssectional comparisons that need testing in longitudinal studies.
Introduction
Alzheimer disease (AD) accounts for 60% to 70% of cases of dementia with an estimated 4.5 million people with AD in the United States. 1 The clinical diagnosis of AD has an estimated sensitivity of 68% to 100% and specificity of 65% to 91% when compared to gold standard neuropathological diagnosis that relies on the presence and abundance of extracellular amyloid (Ab) plaques and intracellular neurofibrillary tangles (NFTs). 2 Clinical symptoms likely appear after significant deposition of amyloid has already occurred, 3 and amyloid deposition begins several years before clinical symptoms of dementia develop. 4, 5 N-methyl-11 C-2-(4-methylaminophenyl)-6-hydroxybenzothiazole (also known as 11 C-6-OH-BTA-1 or Pittsburgh compound B [ 11 C-PIB]) is an amyloid-binding positron emission tomography (PET) tracer. 11 C-PIB binds to fibrillar amyloid with no detectable binding to soluble Ab forms or neurofibrillary tangles under PET study conditions. 6 Regional 11 C-PIB binding correlates with amyloid plaques and vascular amyloid at autopsy. 7, 8 In clinical studies, compared to healthy control individuals, patients with AD have higher 11 C-PIB binding in the prefrontal, precuneus, parietal, and cingulate regions, with the least binding differences in the medial temporal lobe, visual, sensory, and motor cortex. 3, [9] [10] [11] [12] Some control individuals also show increased binding, 9, 10, 13 which may herald a future diagnosis of AD. 10, 14 Less work has been done with 11 C-PIB in patients with mild cognitive impairment (MCI), which is associated with an increased likelihood of conversion to AD. 11 C-PIB studies in small samples suggest that approximately two thirds of patients with amnestic MCI show 11 C-PIB retention similar to AD, while one third are in the healthy control range. 9, [15] [16] [17] [18] In MCI, amyloid positive 11 C-PIB PET may indicate an increased likelihood of conversion to AD. 19 An older, more widely available technique is fluorodeoxyglucose ( 18 F-FDG) PET. Relative hypometabolism in the parietotemporal and posterior cingulate regions characterizes patients with AD and distinguishes them from healthy CTRs, though it may not be highly specific to AD. 20,21 18 F-FDG PET studies in small samples of patients with MCI show that parietotemporal and posterior cingulate hypometabolism may characterize future converters to AD. 22, 23 As summarized in Table 1 , there is growing, but still limited, published data on the comparative and conjoint use of 11 C-PIB PET and 18 F-FDG PET in elderly cognitively impaired patients. 3, 11, 24 To examine the degree to which these PET tracers, individually and combined, distinguish patients with mild AD, MCI, and healthy age-matched controls (CTR), we conducted a PET study using 11 C-PIB and 18 F-FDG PET.
Methods Patients
Patients with MCI and mild AD presented with memory complaints to a Memory Disorders Center at New York State Psychiatric Institute/Columbia University. Based on consensus diagnosis, patients with AD met National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable AD. 32 Folstein Mini-Mental State Exam (MMSE) >16 was required for study inclusion. In MCI and CTR, a neuropsychological test battery was administered. This comprised of the MMSE, SRT (12-item, 6-trial Selective Reminding Test), Wechsler Memory Scale (WMS) Visual Reproduction Test, Category Fluency (Animal Naming and Letter Fluency), Boston Naming 60-item, Boston Diagnostic Aphasia Examination (BDAE) sentence repetition and comprehension, Wechsler Adult Intelligence Scale revised (WAIS-R) similarities, digit symbol and block design, and the Alzheimer's Disease Assessment Scale (ADAS-cog).
Patients with AD received only the MMSE, SRT, and ADAS-cog, and hence, only these 3 cognitive measures were evaluated in analyses.
Amnestic MCI was diagnosed by Petersen criteria 33 requiring subjective memory complaints and either SRT immediate or delayed recall scores >1.5 SD below age-and educationadjusted norms in the absence of impairment in activities of daily living. Patients with nonamnestic MCI were required to score >1.5 SD below norms on any nonmemory test and meet the same clinical criteria. All CTRs were required to have MMSE !27 with recall !2 of 3 objects at 5 minutes, have SRT total and delayed recall scores within 1 SD of age-adjusted norms, and not have a current diagnosis of any Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition; DSM-IV) axis I psychiatric disorder, neurological disorder, or acute medical illness. Family history of dementia was not an exclusion criterion. Patients receiving warfarin were excluded, as were all patients with any contraindication to magnetic resonance imaging (MRI) or PET imaging. Controls were group matched to patients on age and sex. Five healthy CTRs were recruited by advertisement (of 21 patients who passed a telephone screen and then had in-person evaluation and testing) and 13 CTRs were recruited during their participation in a long-term follow-up study in the clinic. All participants signed informed consent in this institutional review board (IRB)-approved protocol.
C-PIB Synthesis
The full radiosynthesis of 11 C-6-OH-BTA-1 is described elsewhere. 34 The average yield was found to be 14.5% at end of synthesis with a specific activity >37 GBq/mmol.
Positron Emission Tomography Imaging
Head movement was minimized using a polyurethane immobilizer molded around the head. Positron emission tomography images were acquired on an ECAT EXACT HRþ (Siemens/ CTI, Knoxville, TN). After a 10-minute transmission scan, mean 500.71 (SD 160.48) MBq of 11 C-PIB was administered intravenously as a bolus over 30 seconds. Emission data were collected in a three-dimensional (3D) mode for 90 minutes, binning over 18 frames of increasing duration (3 Â 20 seconds, 3 Â 1 minute, 3 Â 2 minutes, 2 Â 5 minutes, and 7 Â 10 minutes). Twenty-nine arterial blood samples (each 0.3 mL) were drawn during the scan by pump every 10 seconds for 2 minutes and then every 20 seconds for 2 minutes, followed by manual draws at 6, 12, 20, 30, 40, 50, 60, 80 , and 90 minutes after radioactivity injection. These samples were centrifuged and radioactivity in the plasma measured in the well counter. 12 Images were reconstructed to 128 Â 128 matrix (pixel size of 2.5 Â 2.5 mm 2 ). Reconstruction was performed with attenuation correction using the transmission data, and scatter correction was done using a model-based approach. 35 The reconstruction filter and estimated image filter were Shepp 0.5 (2.5 full width half maximum (FWHM), Z filter was all pass 0.4 (2.0 FWHM), and the zoom factor was 4.0, leading to a final image resolution of 5.1 mm FWHM at the center of the field of view (FOV). 36 
Metabolite Analyses
The percentage of radioactivity in plasma as unchanged 11 C-BTA was determined by high-performance liquid chromatography (HPLC), with blood samples taken at 2, 6, 12, 20, 40, 60, and 90 minutes after radioactivity injection for metabolite analysis. Metabolite and free fractions were collected based on a Bioscan gamma detector and assayed on a Packard Instruments Gamma Counter (Model E5005). All acquired data were subjected to correction for background radioactivity and physical decay to calculate the percentage of the parent compound in the plasma at different time points. To reaffirm that the retention time of the parent compound had not shifted during the course of the metabolite analysis, a quality control sample of 11 C-BTA was injected at the beginning and the end of the study. The percentage of radioactive parent obtained was used for the measurement of metabolite-corrected arterial input functions. The 18 F-FDG study was conducted 1 hour after the 11 C-PIB scan with the same scanner, scanning mode, positioning, and reconstruction matrix. After a 10-minute transmission scan, a bolus injection of 18 F-FDG (mean 178.47, SD 11.92 MBq) was administered intravenously. Emission data were acquired in 3D mode for 60 minutes with 26 frames of increasing duration (8 Â 15 seconds, 6 Â 30 seconds, 5 Â 1 minutes, 4 Â 5 minutes, and 3 Â 10 minutes). Thirteen arterial blood samples (each 0.3 mL) were drawn during the scan (by pump every 10 seconds for 90 seconds and then every 30 seconds for 2 minutes, followed by manual draws at 5, 20, 40, and 60.5 minutes). These samples were centrifuged and radioactivity in the plasma measured in the well counter. 12 Blood glucose was measured by a glucometer for calculation of the regional cerebral metabolic rate for glucose (rCMRGlu). 37 Of the 60 patients, 11 C-PIB scans were completed in 58 patients, of whom 53 subjects had arterial lines. 18 F-FDG scans were completed in 56 of the 60 patients, of whom 52 patients had arterial lines.
Magnetic Resonance Imaging
Magnetic resonance images (MRIs) were acquired using a 1.5T Signa Advantage system (first 17 patients: 8 CTR, 3 MCI, and 6 AD) or a 3T GE scanner (next 42 patients: 10 CTR, 20 MCI, and 12 AD). All scans from the 1.5T scanner were acquired in the coronal plane with the following parameters: 3D spoiled gradient recalled acquisition in the steady state; repetition time (TR) ¼ 34 milliseconds, echo time (TE) ¼ 5 milliseconds, flip angle (FA) ¼ 45 , 1.5-mm slice thickness (zero gap), 124 slices, FOV 220 Â 160 mm. All images were reconstructed to a size of 256 Â 256 mm, with a resolution of 1.5 Â 0.86 Â 0.86 mm. Coronal scans from the 3T scanner were acquired with the following parameters: TR ¼ 5.4 milliseconds, TE ¼ 2.1 milliseconds, FA ¼ 11 , 1-mm slice thickness (zero gap), 160 slices, FOV ¼ 256 Â 256 mm. All images from the 3T were reconstructed to a size of 256 Â 256 mm, with an isotropic resolution of 1 Â 1 Â 1 mm.
The regions of interest (ROIs) chosen for the analysis were based on published studies of 11 C-PIB PET and 18 F-FDG in cognitively impaired patients (Table 1) . A trained, experienced technician drew the prefrontal, cingulate, parietal cortex, and precuneus (left and right) ROIs using atlas-based approaches 38 on MRI scans. 10, 39 The technician also drew the anatomical boundaries for the hippocampus and parahippocampal gyrus, using reliable, published methods. 40 Regions of interest were transferred to motion-corrected and MRI-coregistered PET images. 
Image Analysis Platform

Positron Emission Tomography Image Processing
To correct for subject motion, denoising filter techniques were applied to all PET images starting at frame 5 (2.5 minutes for 11 C-PIB, 1.1 minutes for 18 F-FDG). Frame 8 (5.0 minutes for 11 C-PIB, 1.9 minutes for 18 F-FDG) was the reference to which all other frames were aligned using rigid body FLIRT. The mean of the motion-corrected frames was registered, using FLIRT, to each subject's BET skull stripped MRI. The resultant transform was applied to the entire motion-corrected PET data set.
C-PIB Kinetic Analysis
The cerebellum is nearly devoid of amyloid plaques in postmortem analysis of patients with AD 41 and cerebellar gray matter (GM) shows little 11 C-PIB retention in CTR and AD. 3 Therefore, a ROI that included the entire cerebellum was drawn on the MRI. A binary mask of this ROI was created. To correct the cerebellar ROI to include GM only, unprocessed MRI images were segmented using SPM5 to derive the probabilistic GM (GM p ) map. The GM map and all individual PET frames were multiplied (masked) by the cerebellar binary mask. On a frame-by-frame basis, the sum of all voxels in each masked PET image was divided by the sum of all voxels in the masked GM map to derive the GM cerebellar time-activity curve.
C-PIB (BP ND ) PET Modeling
In the 58 patients who completed the 11 C-PIB scan, BP ND was calculated for each ROI using the Logan graphical method 42 from 90-minute PET data, using the GM probability corrected time-activity curve of the cerebellum as reference (primary analyses for generalizability). The Logan method is stable, has high test-retest reliability, 43 and is sensitive to small changes in 11 C-PIB when compared to quantification using an arterial input function. 44 In this study, binding potential in Plasma (arterial input) (BP p ) was also calculated using the Logan graphical method with an arterial input function (n ¼ 53, secondary analyses). (Binding Potential (Non-displaceable) BPND refers to the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in tissue. BPND is the typical measurement from reference tissue methods, as it compares the concentration of radioligand in receptor-rich to receptor-free regions).
F-FDG Kinetic Analysis
For comparability to the 11 C-PIB analyses, the rCMRGlu ratio of each ROI to cerebellum (sum of 40-60 minutes mean activity) was used (primary analyses for generalizability). In addition, arterial input function corrected data were also evaluated (secondary analyses). 18 F-FDG data were evaluated by a 2-tissue compartment model relating the concentration of free 18 F-FDG and 18 F-FDG-6-PO 4 in the tissue to the 18 F-FDG concentration in plasma through 4 rate constants k Ã 1 to k Ã 4 . 45 The estimates of these rate constants obtained by using the classical iterative nonlinear least squares approach are expected to have optimal statistical accuracy in conjunction with a library of functions of the type e Ày k t c Ã p ðtÞ for a range of y k values. For the 18 F-FDG 2-tissue compartment model, each noisy Time Activity Curve (TAC) curve is regressed on each possible pair of library functions, the smallest sum of weighted squared errors determining the final fit. The limitations of such an approach are that estimation can be negatively affected by poor choices for y k settings and that estimation of time constants is not as precise as when parameters are estimated iteratively. 39 However, an opportune choice of the y k settings is able to obtain estimates of the parameters comparable to those by the standard iterative approach. Furthermore, the rCMRGlu values calculated by using the noniteratively estimated rate constants are significantly less biased than those obtained by the widely adopted and computationally efficient Patlak graphical approach, which underestimates rCMRGlu due to the assumption of k Ã 4 ¼ 0.
Statistical Analyses
Descriptive statistics were used to compare the demographic and clinical variables for the 3 groups of patients (CTR, MCI, AD). For 11 C-PIB BP ND (binding potential, cerebellar reference), separate analyses of variance (ANOVAs) were conducted on each ROI with patient group as the between-subject factor. Similarly, analyses of covariance (ANCOVAs) were conducted with age as covariate. Significant main effects in ANOVA were followed up with 2-tailed t tests for post hoc pairwise comparisons. For the AD-CTR comparison, Cohen's d (effect size) was calculated. A similar set of analyses was conducted for 18 F-FDG rCMRGlu. The mean of all the ROIs for BP ND and rCMRGlu were evaluated in separate ANOVAs with patient group as the between-subject factor. Significant main effects were followed up with 2-tailed t tests for post hoc pairwise comparisons. Across the entire sample, Spearman correlation coefficients between the ROI indices (BP ND or rCMRGlu) in each region and the cognitive assessment measures (MMSE, SRT, ADAS-cog) were examined.
To evaluate the comparative utility of 11 C-PIB BP ND and 18 F-FDG rCMRGlu, receiver operating characteristic (ROC) analyses were conducted to compare their classification accuracy measured by the area under the curve (AUC) with post hoc calculation of sensitivity and specificity. To distinguish diagnostic groups on each ROI, bivariate linear models were applied to the BP ND and rCMRGlu measures (converted to z scores) to test whether the measures differed by diagnostic group after controlling for age and to test whether the group differences were the same for the 2 standardized measures. Model parameters were estimated with generalized estimating equations to use all available data and account for withinsubject correlation between the 2 measures.
Apolipoprotein E genotyping was not done in the majority of patients and hence was not analyzed. When pairwise comparisons were made among 3 diagnostic groups, the a criterion for statistical significance was set conservatively at .0167 (.05/3). Significance levels between 0.02 and 0.05 are reported as trend-level effects.
Results
The sample of 60 patients comprised of 18 patients with CTR, 24 with MCI, and 18 with AD. On average, patients had high education levels and were about 70 years old ( Table 2 ). The 3 groups differed in cognitive test performance on each of the 3 cognitive tests evaluated in all patients (AD worse than MCI worse than CTR). Seventeen of 18 patients with AD, 5 of 24 patients with MCI, and no control subjects were receiving acetylcholinesterase inhibitors or memantine.
C-PIB BP ND (n ¼ 58, Cerebellar Reference)
Across the entire sample, there were no associations between age, sex, education, and BP ND in any ROI (Table 3) and no associations in patients between the use of cholinesterase inhibitors/memantine and BP ND . There were strong inverse correlations between BP ND in the prefrontal, cingulate, parietal, and precuneus regions and the cognitive test scores across the entire sample (Table 3 ). These correlations appeared to be driven by group differences, because they were not as strong when examined within each diagnostic group, partly because of some overlap in BP ND values and the restricted range in cognitive scores within each diagnostic group.
In separate ANOVAs on each ROI with patient group (CTR, MCI, AD) as the between-subject factor, the 3 patient groups differed significantly in BP ND in prefrontal cortex (F ¼ 21.9, P < .001), cingulate (F ¼ 13.2, P < .001), parietal cortex (F ¼ 20.1, P < .001), precuneus (F ¼ 28.7, P < .001), and parahippocampal gyrus (F ¼ 6.2, P ¼ .004) but not in hippocampus (F ¼ 0.4, P ¼ .7). In ANCOVA on each ROI with patient group (CTR, MCI, AD) as the between-subject factor, age was not a significant covariate in any analysis.
In post hoc t tests, BP ND was higher in patients with AD compared to CTR in prefrontal cortex (t ¼ 6.5, P < .0001), cingulate (t ¼ 4.9, P < .001), parietal cortex (t ¼ 6.1, P < .0001), precuneus (t ¼ 7.2, P < .0001), and parahippocampal gyrus (t ¼ 3.4, P ¼ .001) but not in the hippocampus (t ¼ .3, P ¼ .8). In precuneus and prefrontal cortex, only 1 control showed BP ND in the AD range and only 1 patient with AD showed BP ND in the control range (Figure 1 ). BP ND was also higher in patients with AD compared to those with MCI in prefrontal cortex (t ¼ 4.5, P < .0001), cingulate (t ¼ 3.9, P ¼ .0003), parietal cortex (t ¼ 4.8, P < .0001), and precuneus (t ¼ 5.8, P < .0001), with an increase in parahippocampal gyrus (t ¼ 2.7, P ¼ .01) and no difference in hippocampus (t ¼ 0.5, P ¼ .62). In MCI compared to CTR, BP ND was higher in prefrontal cortex (t ¼ 2.3, P ¼ .02) and there were no significant differences in any of the other 5 regions. As seen in Figure 1 , patients with amnestic MCI were similar to patients with AD and had nonsignificantly higher BP ND than patients with nonamnestic MCI (n ¼ 5) and patients with CTR in several ROIs. The small number of patients, particularly in the nonamnestic MCI subsample (n ¼ 5), likely explains the lack of significance in the MCI subgroup comparisons.
For the AD-CTR comparison, the effect size for BP ND was large (>2 SD) for several regions, including precuneus (Cohen's d ¼ 2.81), parietal cortex (d ¼ 2.28), and mean BP ND (d ¼ 2.23).
The results obtained for 11 C-PIB by using the arterial input function (n ¼ 53) led to very similar results with nearly identical significance levels for all comparisons (data available on request) relative to those obtained using the cerebellar reference data.
F-FDG PET (n ¼ 56, Ratio to Cerebellum)
Across the entire sample, sex, age, and education were unrelated to rCMRGlu in any ROI (Table 4 ). Regional cerebral metabolic rate for glucose in the parietal cortex and precuneus correlated strongly with cognitive test scores across the entire sample, with somewhat weaker correlations between rCMRGlu in the hippocampus and cognitive test scores (Table 4 ). Regional cerebral metabolic rate for glucose values did not differ between patients who did and did not receive cholinesterase inhibitors or memantine.
In ANOVAs on each ROI, rCMRGlu differed across the 3 patient groups in parietal cortex (F ¼ 18.4, P < .0001), precuneus (F ¼ 16.8, P < .0001), and cingulate (F ¼ 5.48, P ¼ .007) but not the prefrontal cortex (F ¼ .9, P ¼ .40), parahippocampal gyrus (F ¼ 1.0, P ¼ .39), or hippocampus (F ¼ 1.7, P ¼ .20). In ANCOVA on each ROI, age was not a significant covariate for any region.
In post hoc t tests, rCMRGlu was lower in patients with AD compared to those with CTR in parietal cortex (t ¼ 5.5, P < .0001), precuneus (t ¼ 5.2, P < .0001), and cingulate (t ¼ 3.1, P ¼ .004) but not in other regions. Regional cerebral metabolic rate for glucose was lower in patients with AD compared to those with MCI in parietal cortex (t ¼ 5.2, P < .0001), precuneus (t ¼ 5.0, P < .0001), and cingulate (t ¼ 2.7, P ¼ .008) but not in other regions. Regional cerebral metabolic rate for glucose showed no significant differences between MCI (total MCI or amnestic MCI) and control individuals in any ROI. Regional cerebral metabolic rate for glucose did not differ significantly between patients with amnestic MCI and those with nonamnestic MCI in any ROI, primarily because the small number of patients with nonamnestic MCI (n ¼ 5) limited statistical power (Figure 2) . For the AD-CTR comparison, for rCMRGlu, the effect size (Cohen's d) was 1.59 for precuneus, 1.72 for parietal cortex, and 1.22 for mean value.
Arterial Input Function-Derived rCMRGlu Analyses (n ¼ 52, Absolute Quantification) These analyses revealed similar but slightly weaker results to those obtained by using the cerebellar ratio. Regional cerebral metabolic rate for glucose was lower in patients with AD compared to those with CTR in parietal cortex (t ¼ 3.0, P ¼ .006) and precuneus (t ¼ 3.3, P ¼ .003), tended to be lower in cingulate (t ¼ 2.1, P < .04), and did not differ in prefrontal cortex, parahippocampal gyrus, and hippocampus. Regional cerebral metabolic rate for glucose tended to be lower in patients with AD compared to those with MCI in parietal cortex (t ¼ 2.1, P ¼ .04) and precuneus (t ¼ 2.4, P ¼ .02) but not in prefrontal cortex (t ¼ 0.50, P ¼ .6), cingulate (t ¼ 1.2, P ¼ .25), parahippocampal gyrus (t ¼ 0.0, P ¼ .97), and hippocampus (t ¼ 0.90, P ¼ .4). Regional cerebral metabolic rate for glucose showed no significant differences in any ROI between MCI and control individuals or between patients with amnestic and nonamnestic MCI.
Mean ROI ( 11 C-PIB BP ND and 18 F-FDG rCMRGlu)
In ANOVA on the unweighted mean of all the ROIs examined, the 3 patient groups differed significantly in 11 C-PIB BP ND (F ¼ 19.6, P < .0001) and rCMRGlu (F ¼ 9.2, P ¼ .0004). Mean 11 C-PIB BP ND was higher in AD compared to CTR (t ¼ 6.0, P < .0001) and AD compared to MCI (t ¼ 4.7, P < .0001) but not MCI compared to CTR (t ¼ 1.6, P ¼ .11). Mean rCMRGlu was higher in AD compared to CTR (t ¼ 3.9, P ¼ .0003) and AD compared to MCI (t ¼ 3.7, P ¼ .0005) but not MCI compared to CTR (t ¼ 0.4, P ¼ .66). In ANCOVA on mean 11 C-PIB BP ND , the groups differed significantly (F ¼ 19.2, P < .0001) and age was not a significant covariate (F ¼ 0.01, P ¼ .9). In ANCOVA, on mean rCMRGlu in the 3 patient groups, the groups differed significantly (F ¼ 9.2, P ¼ .0004) and age was not a significant covariate (F ¼ 0.53, P ¼ .47).
C-PIB With 18 F-FDG Correlations
Spearman correlation coefficients between 11 C-PIB BP ND and rCMRGlu within each ROI ranged from À.01 to À.4 and the correlation between mean ROI values was À.13, indicating relative dissociation between the 11 C-PIB and 18 F-FDG measures. Figure 2 . Fluorodeoxyglucose ( 18 F-FDG) PET regional cerebral metabolic rate for glucose (rCMRGlu) in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy controls (CTR). Regional cerebral metabolic rate for glucose was derived from regional analysis of MR coregistered 18 F-FDG PET images with ratio of each region of interest (ROI) to cerebellum represented on the y axis. aMCI indicates amnestic MCI; CIN ¼ cingulate; HIP ¼ hippocampus; non-aMCI ¼ nonamnestic MCI; PAR ¼ parietal cortex; PCN ¼ precuneus; PET ¼ positron emission tomography; PFC ¼ prefrontal cortex; PHG ¼ parahippocampal gyrus.
Comparative Utility of 11 C-PIB BP ND and 18 F-FDG rCMRGlu
For BP ND , the most prominent difference between AD and CTR was in precuneus, consistent with the literature (Figures 1 and 3) .
For rCMRGlu, the most prominent difference between AD and CTR was in parietal cortex, consistent with the literature (Figures 2 and 3) . In the sample of 16 patients with AD and 17 patients with CTR (total n ¼ 33), who had both PET scans, Figure 3 . Comparison of binding potential (BP ND ; left) and regional cerebral metabolic rate for glucose (rCMRglu; right) data derived from positron emission tomography (PET) 11 C-PIB and 18 F-FDG scans, respectively, for controls (CTR), patients with mild cognitive impairment (MCI), and patients with Alzheimer disease (AD). All PET data were nonlinearly registered, using each individual's magnetic resonance imaging (MRI), to the Statistical Parametric Mapping (SPM5) MNI single-subject MRI template using the Automated Registration Toolbox (ART). MNI space BP ND and rCMRGlu maps were averaged voxel-by-voxel in the AD (first row), MCI (second row), and CTR (third row) groups. The middle color bar represents the BP ND (left side) and rCMRglu (right side) value in the images. Arrows point to regions of interest for the prefrontal cortex (PFC), precuneus (PCN), anterior cingulate (ACN), and hippocampus (HIP). Montreal Neurological Institute (MNI).
based on the predicted probability of an AD diagnosis using separate logistic regression models, for precuneus BP ND , estimated AUC ¼ 0.938 and parietal cortex rCMRGlu, estimated AUC ¼ 0.915. Combining these 2 PET measures led to an estimated AUC ¼ 0.989. For the same AD-CTR comparison, for mean BP ND estimated AUC ¼ 0.923 was nonsignificantly higher than for mean rCMRGlu estimated AUC ¼ 0.800.
To evaluate sensitivity and specificity for BP ND in precuneus and rCMRGlu in parietal cortex, ROC analyses were used to derive the cutoff points that maximized the product of sensitivity and specificity. For the precuneus BP ND cut point of 0.4087 (values above this considered abnormal), for AD versus CTR, sensitivity was 0.944 and specificity was 0.944, and for MCI versus CTR, sensitivity was 0.273 and specificity was 0.944. For the mean BP ND cut point of 0.1948 (values above this considered abnormal), for AD versus CTR, sensitivity was 0.944 and specificity was 0.944, and for MCI versus CTR, sensitivity was 0.273 and specificity was 0.944. For the parietal cortex rCMRGlu cut point of 1.0301 (values below this considered abnormal), for AD versus CTR, sensitivity was 0.875 and specificity was 0.882, and for MCI versus CTR, sensitivity was 0.174 and specificity was 0.882. For the mean rCMRGlu cut point of 0.9574 (values below this considered abnormal), for AD versus CTR, sensitivity was 0.813 and specificity was 0.706, and for MCI versus CTR, sensitivity was 0.217 and specificity was 0.706.
In comparing diagnostic group differences in BP ND to diagnostic group differences in rCMRGlu, bivariate linear models controlling for age were applied to the PET regional measures (converted to z scores). In distinguishing AD from CTR, BP ND was significantly better than rCMRGlu only in prefrontal cortex (P ¼ .015) mainly because prefrontal cortex rCMRGlu did not differ in the 2 diagnostic groups (P ¼ .42). Mean BP ND was not significantly better than mean rCMRGlu in classifying AD versus CTR (P ¼ .37). BP ND was not significantly different from rCMRGlu in distinguishing AD from MCI or MCI from CTR in any region or mean values.
Discussion
11
C-PIB BP ND was higher in patients with AD compared to CTR with a large effect size for precuneus, parietal cortex, and mean values. There was near-complete separation in precuneus, which appears to be the region most likely to show differences between AD and CTR. 10 11 C-PIB BP ND was also higher in AD compared to CTR in prefrontal and cingulate cortex but not in the hippocampus, consistent with the literature. 3, 9, 11 These findings support the relative regional distribution of amyloid reported in other 11 C-PIB studies that also found increased prefrontal, parietal, and precuneus uptake 3, 9 and is consistent with autopsy data showing that in early AD, amyloid deposition is greater in the frontal and parietal cortex than in the hippocampus. 5 In the ROIs examined, 11 C-PIB BP ND differences occurred in AD compared to CTR and AD compared to MCI. Mild cognitive impairment differed significantly from CTR only in prefrontal cortex. 15, 18, 31, 46 Based on the cutoff value used in this study, the majority of patients with MCI had BP ND like those with CTRs and a minority had BP ND like those with AD. Possible explanations are the inclusion of patients with nonamnestic MCI (n ¼ 5, of whom 4 scored below the cutoff in parietal cortex and precuneus) in the MCI sample and the fact that approximately one third of the MCI sample had been followed in the clinic for 1 to 2 years without conversion to dementia. The latter group would be less likely to have AD brain pathology than patients with MCI who present for initial evaluation.
Controls with high 11 C-PIB retention were rare in our sample, with little overlap between AD and CTR in precuneus and prefrontal cortex (Figure 1) . In contrast, other reports show high 11 C-PIB retention in approximately 20% of healthy elderly control individuals. 10 Different criteria used to select control subjects may partly account for these differences across studies. In our study, impairment on neuropsychological tests was a strict exclusion criterion for healthy control individuals, in contrast to the use of the Clinical Dementia Rating of global cognitive/functional ability in some studies that may have allowed for the inclusion of control individuals with mild neuropsychological deficits. 10 Initial follow-up studies suggest that increased 11 C-PIB retention is associated with an increased likelihood of healthy CTRs converting to MCI and patients with MCI converting to AD. 14, 18 In a recent study, PIB-positive patients with MCI were more likely to convert to AD than PIB-negative patients, and faster converters had higher PIB retention levels at baseline than slower converters. 19 In patients diagnosed with AD, there may be no increase 47 or a small increase in 11 C-PIB retention during follow-up. 15,27 18 F-FDG rCMRGlu differed among the 3 patient groups in the precuneus, parietal cortex, and cingulate but not in the prefrontal cortex, hippocampus, and parahippocampal gyrus. These findings were confined to the AD-CTR and AD-MCI comparisons, and MCI-CTR comparisons were not significant. The findings are consistent with the literature on parietal and posterior cingulate metabolic deficits distinguishing AD from CTR, but in this sample, there were no significant differences in medial temporal regions. Other reports indicate that both parietal and temporal metabolic deficits distinguish AD from CTR. 20 We observed few MCI-CTR differences, but another report in a small sample suggests that regional decrease in rCMRGlu in parietal and posterior cingulate may be superior to 11 C-PIB in distinguishing MCI from CTR. 24 Although there were no associations for rCMRGlu measures with age in this sample, changes are known to occur with aging in patients with AD, with younger patients with AD clearly showing the typical parietotemporal hypometabolism while older patients with AD have a more global reduction in glucose metabolism. 20 When both BP ND and rCMRGlu were compared directly, BP ND was marginally, but nonsignificantly, superior to rCMRGlu in distinguishing AD from CTR and AD from MCI. Figure 3 shows that there are visible uptake differences and different patterns of uptake across the 3 groups using the 2 tracers. The AUC analysis on an ROI level showed strong utility for BP ND and possibly greater utility for the combination of BP ND and rCMRGlu, and this approach may have potential for better segregating patient populations and predicting conversion to AD in longitudinal studies of patients with MCI. Alternative assessments include total cortical binding 10 or visual assessment by a radiologist, 11 both of which have shown moderate to strong sensitivity and specificity in separating AD from CTR, but less information is available on the use of these approaches in MCI. With respect to structural imaging, regional PIB retention and MRI hippocampal atrophy may provide complementary information in MCI and AD. 16 Of note, approximately 5% to 10% of patients diagnosed as AD in an academic specialty center, as in this study, do not have AD when patients are followed to autopsy. 2 11 C-PIB retention in several regions showed strong inverse correlations with cognitive measures across the sample, consistent with some studies in patients with MCI and AD 48, 49 and elderly patients with cognitive decline, 14 but not all studies show such strong correlations. 13,16 18 F-FDG rCMRGlu in the parietal cortex and precuneus showed the strongest correlations with cognitive measures, and rCMRGlu in the hippocampus also showed significant correlations with some cognitive measures. These correlations were not as strong when examined within each diagnostic group, partly because of some overlap in BP ND values and the restricted range in cognitive scores within each diagnostic group.
These neuroimaging-clinical associations are consistent with the parietal, temporal, and posterior cingulate pathology known to occur in AD. 4 For 11 C-PIB, results using the Logan method and a cerebellar reference region were very similar to those obtained using the arterial input function, supporting other work indicating that an arterial line may not be necessary for 11 C-PIB scans. 44 Furthermore, the FDG results using a ROI to cerebellar ratio to provide direct comparability to the 11 C-PIB analyses 24 were as strong or stronger than those obtained with the arterial input function and absolute quantification, supporting the use of this analytic approach in MCI and mild AD. Visual reads or voxelbased statistical approaches may be more efficient than ROI methods for 18 F-FDG analyses when used for other purposes.
Limitations included the lack of apolipoprotein E genotyping in the majority of patients; the presence of the apo E e4 allele has been shown to be associated with increased PIB retention. 50, 51 The study was cross-sectional, and follow-up data to examine the prognostic implications of the baseline PET findings are clearly needed. Conclusion 11 C-PIB PET BP ND strongly distinguished diagnostic groups, and when combined with 18 F-FDG PET rCMRGlu, this effect became stronger suggesting that the 2 techniques provide complementary information. The results of this study and the literature suggest that the potential added value of complementary PET techniques to the information obtained from clinical evaluation and neuropsychological testing needs to be clarified in longitudinal studies. Although amyloid deposition in the brain is known to occur very early in AD, it remains unclear whether 11 C-PIB PET shows increased retention before 18 F-FDG PET shows decreased rCMRGlu prior to the clinical diagnosis of AD. 27, 31 Furthermore, the potential of 11 C-PIB PET as a surrogate marker in clinical trials, particularly of antiamyloid agents, needs to be established.
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